SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-251515"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-251515" > EGFR-expression in ...

  • Carlsson, JörgenUppsala universitet,Medicinsk strålningsvetenskap (författare)

EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides

  • Artikel/kapitelEngelska2015

Förlag, utgivningsår, omfång ...

  • 2015
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-251515
  • urn:nbn:se:uu:diva-251515urn
  • https://doi.org/10.2478/raon-2014-0015DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:130880383URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • gratis
  • Background. There is limited effect of tyrosine kinase inhibitors or "naked" antibodies binding EGFR or HER2 for therapy of metastasized urinary bladder canter and these methods are therefore not routinely used. Targeting radionuclides to the extracellular domain of the receptors is potentially a better possibility. Methods. EGFR- and HER2-expression was analyzed for primary tumors and corresponding metastases from 72 patients using immunohistochemistry and the internationally recommended HercepTest. Intracellular mutations were not analyzed since only the receptors were considered as targets and intracellular abnormalities should have minor effect on radiation dose. Results. EGFR was positive in 71% of the primary tumors and 69% of corresponding metastases. Local and distant metastases were EGFR-positive in 75% and 66% of the cases, respectively. The expression frequency of HER2 in related lesions was slightly higher (data from previous study). The EGFR-positive tumors expressed EGFR in metastases in 86% of the cases. The co-expression of EGFR and HER2 was 57% for tumors and 53% for metastases. Only 3% and 10% of the lesions were negative for both receptors in tumors and metastases, respectively. Thus, targeting these receptors with radionuclides might be applied for most patients. Conclusions. At least one of the EGFR- or HER2-receptors was present in most cases and co-expressed in more than half the cases. It is therefore interesting to deliver radionuclides for whole-body receptor-analysis, dosimetry and therapy. This can hopefully compensate for resistance to other therapies and more patients can hopefully be treated with curative instead of palliative intention.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Wester, KennethUppsala universitet,Institutionen för immunologi, genetik och patologi(Swepub:uu)kennwest (författare)
  • De La Torre, ManuelUppsala universitet,Molekylär och morfologisk patologi(Swepub:uu)manutorr (författare)
  • Malmström, Per-UnoUppsala universitet,Urologkirurgi(Swepub:uu)perunoms (författare)
  • Gardmark, Truls (författare)
  • Malmstrom, PU (författare)
  • De La Torre, M (författare)
  • Wester, K (författare)
  • Carlsson, J (författare)
  • Gardmark, TKarolinska Institutet(Swepub:ki)d7f28d2561f6f221cba6f4db9b7336ce (författare)
  • Uppsala universitetMedicinsk strålningsvetenskap (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Radiology and Oncology49:1, s. 50-581318-20991581-3207

Internetlänk

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy